Anti-Human CD2 [Clone LO-CD2a] — Purified in vivo PLATINUM™ Functional Grade
Anti-Human CD2 [Clone LO-CD2a] — Purified in vivo PLATINUM™ Functional Grade
Product No.: C529
Clone LO-CD2a Target CD2 Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names LFA-2, T11, SRBC, BTI-322 Isotype Rat IgG2b κ Applications ELISA , FA , FC , in vivo |
Antibody DetailsProduct DetailsReactive Species Human Host Species Rat Recommended Isotype Controls Recommended Dilution Buffer Immunogen Purified human T Lymphocytes Product Concentration ≥ 5.0 mg/ml Endotoxin Level <0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM<sup>TM</sup> antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2-8°C Wet Ice RRIDAB_2828910 Additional Applications Reported In Literature ? FC, FA, ELISA Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Anti-CD2 antibody (clone LO-CD2a) activity is directed against human CD2. Background Human CD2 is a 351 amino acid transmembrane glycoprotein that is part of the immunoglobulin superfamily1, 2. CD2 is expressed on the surface of mature T cells, most NK cells, thymocytes, dendritic cells, and 9-12% of bone marrow cells. CD2 participates in T cell and NK cell activation and is important for thymocyte development and assembly of the immunological synapse1. However, the role of CD2 in murine immunity is not always consistent with its function in higher animals. CD2 is known to bind to lymphocyte-associated antigen3 (CD58 and its murine analog CD48) as well as CD59. LO-CD2a was developed as an immunosuppressive agent for use in organ allotransplantation3, 4. LO-CD2a strongly inhibits mixed lymphocyte culture3 and induces T cell apoptosis5. Additionally, LO-CD2a induces very low levels of cytokine release, inhibits cytokine production induced by OKT3, and induces human T cell hyporesponsiveness3. The immune response is inhibited as a result of cell lysis by antibody-dependent cell mediated cytotoxicity (ADCC) induced by NK cells and activated monocytes and from CD2 down-modulation on CD2+ cells6. LO-CD2a also strongly inhibits proliferation of peripheral blood mononuclear cells stimulated with soluble OKT3. LO-CD2a has demonstrated immunosuppressive activity in vitro and effective T cell depletion in vivo. Unresponsiveness upon restimulation with the same antigen makes LO-CD2 distinct from other anti-CD2 antibodies7. Antigen Distribution CD2 is expressed on all mature human T cells, most thymocytes, NK cells and a small proportion of bone marrow cells. Ligand/Receptor CD58 (LFA-3), CD48, CD59, CD15 PubMed NCBI Gene Bank ID UniProt.org Research Area Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. In Vivo Applications of Clone LO-CD2a in MiceClone LO-CD2a, also known as BTI-322, is a rat monoclonal antibody targeting human CD2—a glycoprotein expressed on T cells, NK cells, most thymocytes, and a small subset of bone marrow cells. While endogenous mouse CD2 is not the primary target of LO-CD2a, the antibody finds significant utility in humanized mouse models—mice engrafted with human immune cells—for several in vivo research applications. Key In Vivo Applications
Mechanism of Action
Additional Considerations
Summary Table
ConclusionIn vivo, LO-CD2a is chiefly used in humanized mouse models to deplete human CD2+ T cells, prevent graft rejection, and study mechanisms of immunosuppression. Its actions are mediated by ADCC and CD2 down-modulation, leading to durable T cell hyporesponsiveness with minimal cytokine release, making it a valuable tool for transplantation immunology and human immune cell research in mice. Commonly used antibodies or proteins paired with LO-CD2a in the literature include anti-CD3, anti-TCR Vβ family-specific antibodies, and markers for monocytes and other T cell-related surface proteins. Key combinations and supporting details:
These combinations reflect common research aims such as T cell depletion, tolerance induction, immunosuppression, and dissecting specific immune cell interactions in transplantation or autoimmunity models. The key findings from clone LO-CD2a citations in scientific literature center on its unique immunosuppressive mechanisms, effective T cell depletion, and induction of antigen-specific immune unresponsiveness, distinguishing it from other anti-CD2 antibodies. Main findings include:
These findings collectively position LO-CD2a as a distinctive tool for immunosuppression and tolerance induction, with applications in transplantation and preclinical immune modulation studies. Dosing regimens of clone LO-CD2a (anti-human CD2 monoclonal antibody) vary across mouse models and are not standardized; they are typically determined by the experimental context, especially the presence of human T cells in humanized or chimeric mice, since LO-CD2a targets human CD2 and does not react to mouse CD2.
Protocols should be customized for each experimental setup, with close consideration of mouse strain, engraftment of human cells, and desired immunological effect. If further precision is needed, dose titration and pilot studies are advised before definitive experiments, due to possible severe reactions at higher doses, particularly with IV administration. References & Citations1. Binder C, Cvetkovski F, Sellberg F, et al. Front Immunol. 11:1090. 2020. 2. Bierer BE, Sleckman BP, Ratnofsky SE, et al. Annu Rev Immunol. 7:579–599. 1989. 3. Latinne D, De La Parra B, Nizet Y, et al. Int Immunol. 8(7):1113-1119. 1996. 4. Bazin H, Latinne D, et al, inventors; Biotransplant Inc, assignee. LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation. US patent 6,849,258 B1. Feb 1, 2005. 5. Dumont C, Déas O, Mollereau B, et al. J Immunol. 160(8):3797-3804. 1998. 6. Nizet Y, Chentoufi AA, de la Parra B, et al. Transplantation. 69(7):1420-1428. 2000. 7. Xu Y, Kolber-Simonds D, Hope JA, et al. Clin Exp Immunol. 138(3):476-483. 2004. Technical ProtocolsCertificate of Analysis |
Formats Available
Prod No. | Description |
---|---|
C530 | |
C537 | |
C538 | |
C539 | |
C540 | |
C541 | |
C542 | |
C543 | |
C509 | |
C529 |
